Además de la determinación de la dosis y el esquema para los estudios de Fase II, los resultados de actividad observados en estos estudios de Fase I han orientado las indicaciones para los estudios de fase II, concretamente, durante el año 2015 se iniciarán estudios específicos en las indicaciones de Cáncer de Mama y Cáncer Colorectal.
Continúa además el reclutamiento del estudio fase I en combinación con Gemcitabina en dos centros en España y Estados Unidos.
***************************************************+
PM060184 is a marine-derived synthetically-produced compound with strong in vitro and in vivo antitumour activity and a favorable safety profile. In Phase I studies.
Situation Overview
PM060184 belongs to a new family of tubulin-binding agents originally isolated from the marine sponge Lithoplocamia lithistoides. This compound is currently produced by total synthesis and is under evaluation in clinical studies in patients with advanced cancer diseases.
Mechanism of Action
PM060184 has a potent antitumor activity in a panel of different tumor xenograft models. PM060184 induces disorganization and disruption of the microtubule network as well as aberrant mitotic spindle multipolarization and chromosome missegregation. These effects give rise to prometaphase arrest and formation of multinucleated cells. Then, cells enter to caspase-driven apoptosis or are arrested in a pseudo-senescent state.